Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Miscellaneous

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or
the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601
monotherapy and in combination with gemcitabine.
Miscellaneous
I
Davis, Elizabeth
NCT05389462
VICCPHI2225

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.